Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Oct 20.
doi: 10.1007/s40615-025-02702-4. Online ahead of print.

Sickle Cell Disease and Gene Therapy Among African Americans: A Dilemma and Challenge

Elizabeth Armstrong-Mensah  1 , Ato Kwamena Tetteh  2 , Emmanuel Ofori  3 , David Armstrong-Mensah  4
Affiliations
Review

Sickle Cell Disease and Gene Therapy Among African Americans: A Dilemma and Challenge

Elizabeth Armstrong-Mensah et al. J Racial Ethn Health Disparities. .

Abstract

Sickle cell disease (SCD) is a debilitating genetic disorder of the red blood cells. In severe cases, it may lead to pain, hospitalization, stroke, heart disease, organ damage, acute chest syndrome caused by blockages in the lungs, and chronic complications which may affect the kidneys, lungs, joints, and eyes. In the United States (US), about 100,000 people have SCD, with 90% being African American. Although the US Food and Drug Administration's recently approved groundbreaking base editing gene therapies of Casgevy and Lyfgenia have been declared promising in treating SCD, uptake for the therapies has been low. Though the treatment of SCD through gene therapy has sparked some excitement in the African American community, it is also causing a dilemma and challenges. This paper documents the dilemma and challenges associated with gene therapy among the African American SCD community and what can be done to address them.

Keywords: African Americans; Dilemma; Gene therapy; Gene therapy challenges; Sickle cell disease.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interests: The authors declare no competing interests.

References

    1. Centers for Disease Control and Prevention. Get screened to know your sickle cell status. Centers for Disease Control and Prevention. Published May 15, 2019. Accessed July 7, 2025. www.cdc.gov/sickle-cell/media/fact-sheets/sickle-cell-trait/get-screened...
    1. Sani A, Idrees Khan M, Shah S, et al. Diagnosis and screening of abnormal hemoglobins. Clin Chim Acta. 2024;552:117685. https://doi.org/10.1016/j.cca.2023.117685 . - DOI - PubMed
    1. Walter W, Pohlkamp C, Meggendorfer M, et al. Artificial intelligence in hematological diagnostics: game changer or gadget? Blood Rev. 2023;58:101019. https://doi.org/10.1016/j.blre.2022.101019 . - DOI - PubMed
    1. NHS England. Understanding haemoglobinopathies. GOV.UK. Updated April 23, 2025. Accessed July 7, 2025. https://www.gov.uk/government/publications/handbook-for-sickle-cell-and-...
    1. Hemoglobinopathies. Brigham and Women’s Hospital. Updated April 17, 2002. Accessed July 7, 2025. https://sickle.bwh.harvard.edu/hemoglobinopathy.html